SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-008685
Filing Date
2023-05-09
Accepted
2023-05-09 08:10:07
Documents
62
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sgtx-20230331x10q.htm   iXBRL 10-Q 1603410
2 EX-31.1 sgtx-20230331xex31d1.htm EX-31.1 36591
3 EX-31.2 sgtx-20230331xex31d2.htm EX-31.2 36594
4 EX-32.1 sgtx-20230331xex32d1.htm EX-32.1 15196
  Complete submission text file 0001558370-23-008685.txt   6228584

Data Files

Seq Description Document Type Size
5 EX-101.SCH sgtx-20230331.xsd EX-101.SCH 40070
6 EX-101.CAL sgtx-20230331_cal.xml EX-101.CAL 52544
7 EX-101.DEF sgtx-20230331_def.xml EX-101.DEF 127363
8 EX-101.LAB sgtx-20230331_lab.xml EX-101.LAB 388655
9 EX-101.PRE sgtx-20230331_pre.xml EX-101.PRE 269566
56 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20230331x10q_htm.xml XML 1011893
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39746 | Film No.: 23900078
SIC: 2834 Pharmaceutical Preparations